美国食品药品监督管理局（FDA）已授予Hympavzi®（Marstacimab）补充生物制剂许可申请（sBLA）优先审评资格。该药物旨在治疗存在重大医疗需求的两类血友病A或B患者群体。
优先审评资格的授予，意味着FDA认为该疗法有潜力在安全性或有效性方面为患者提供显著改善。此举有望加速Hympavzi®的审批进程，为亟需新治疗选择的血友病患者带来希望。
美国食品药品监督管理局（FDA）已授予Hympavzi®（Marstacimab）补充生物制剂许可申请（sBLA）优先审评资格。该药物旨在治疗存在重大医疗需求的两类血友病A或B患者群体。
优先审评资格的授予，意味着FDA认为该疗法有潜力在安全性或有效性方面为患者提供显著改善。此举有望加速Hympavzi®的审批进程，为亟需新治疗选择的血友病患者带来希望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.